Search

Author/Creator Strand, V

11. AB0794 Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from two phase 3 studies. (15th June 2017)

Authors:
Strand, V; Vlam, K de; Covarrubias-Cobos, JA; Mease, PJ; Gladman, DD; Hendrikx, T; Kudlacz, E; Graham, D; Wu, J; Chen, L
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
1335
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Issue 12 (27th February 2006)

Authors:
Chung, C P; Thompson, J L; Koch, G G; Amara, I; Strand, V; Pincus, T
Journal:
Annals of the rheumatic diseases
Issue:
Volume 65:Issue 12(2006)
Page Start:
1602
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Issue 6 (17th November 2008)

Authors:
Fleischmann, R; Vencovsky, J; van Vollenhoven, R F; Borenstein, D; Box, J; Coteur, G; Goel, N; Brezinschek, H-P; Innes, A; Strand, V
Journal:
Annals of the rheumatic diseases
Issue:
Volume 68:Issue 6(2009)
Page Start:
805
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Issue 6 (17th November 2008)

Authors:
Smolen, J; Landewé, R B; Mease, P; Brzezicki, J; Mason, D; Luijtens, K; van Vollenhoven, R F; Kavanaugh, A; Schiff, M; Burmester, G R; Strand, V; Vencovský, J; van der Heijde, D
Journal:
Annals of the rheumatic diseases
Issue:
Volume 68:Issue 6(2009)
Page Start:
797
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. FRI0240 Rheumatoid arthritis (RA) impact following treatment with sarilumab: patient reported outcomes using the raid scale from two randomized phase III trials. (15th June 2017)

Authors:
Gossec, L; Strand, V; Proudfoot, C; Chen, C; Guillonneau, S; Kimura, T; Hoogstraten, H van; Mangan, E; Reaney, M
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
575
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. FRI0246 Improvements in health-related quality of life with sirukumab are statistically significant, clinically meaningful, and meet or exceed normative values in rheumatoid arthritis patients with inadequate response to disease-modifying antirheumatic drugs: post hoc analyses of a phase 3 trial. (15th June 2017)

Authors:
Strand, V; McQuarrie, K; Li, N; Ganguly, R
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
578
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. FRI0253 Patient-reported outcomes in patients with rheumatoid arthritis treated with subcutaneous tocilizumab compared with placebo or intravenous tocilizumab in combination with csdmards. (15th June 2017)

Authors:
Strand, V; Lampl, K; Birchwood, C; Pei, J; Tuckwell, K; Finch, R; Kivitz, A; Burmester, G
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
581
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗